Pulmonary Hypertension

A tétel rövid nézete
dc.contributor.advisorLekli, Istvàn
dc.contributor.advisordeptGyógyszerésztudományi Kar
dc.contributor.authorAghakhani, Fatemeh
dc.contributor.departmentDE--Gyógyszerésztudományi Kar
dc.contributor.opponentVasvári, Gábor
dc.contributor.opponentSzőke, Kitti
dc.contributor.opponentdeptGyógyszerésztudományi Kar
dc.date.accessioned2024-05-07T08:36:58Z
dc.date.available2024-05-07T08:36:58Z
dc.date.created2024-04-19
dc.description.abstractPulmonary hypertension (PH) is quickly becoming a major cause for mortality with a prevalence of approximately 1% of the global population, with a growing frequency among the elderly. PH encompasses a group of disorders characterized by an elevated blood pressure in the pulmonary arteries, leading to right heart dysfunction and eventually, heart failure. While PH can arise from various etiologies, including heart and lung disorders, genetic predispositions, and exposure to certain medications, its management remains challenging due to limited treatment options and progressive nature. Endothelin receptor antagonists (ERAs) have emerged as pivotal agents in the therapeutic armamentarium against PH. Numerous clinical trials have demonstrated the efficacy of ERAs in alleviating PH symptoms, enhancing exercise tolerance, and slowing disease advancement. Among the ERAs, most extensively studied are Bosentan, Ambrisentan, and Macitentan, which have demonstrated favorable results across various forms of PH, including idiopathic pulmonary arterial hypertension (IPAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Ongoing research endeavors continue to investigate novel therapeutic targets and treatment regimens, with the ultimate objective of improving outcomes and quality of life for those suffering with PH.
dc.description.coursegyógyszerész
dc.description.courselangangol
dc.description.degreeMSc/MA
dc.format.extent39
dc.identifier.urihttps://hdl.handle.net/2437/369656
dc.language.isoen
dc.rights.accessHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectPulmonary Hypertension
dc.subjectEndothelin Receptor Antagonists
dc.subjectCardiology
dc.subjectCardiopulmonary
dc.subjectBosentan
dc.subjectAmbrisentan
dc.subjectMacitentan
dc.subject.dspaceMedicine
dc.titlePulmonary Hypertension
dc.title.subtitleThe Role of Endothelin Receptor Antagonists in The Treatment of Pulmonary Hypertension
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 2 (Összesen 2)
Nem elérhető
Név:
Thesis_Fatemeh_Aghakhani.pdf
Méret:
1.64 MB
Formátum:
Adobe Portable Document Format
Leírás:
Megjelenítés
Nem elérhető
Név:
3. Declaration_plagium.pdf
Méret:
61.8 KB
Formátum:
Adobe Portable Document Format
Leírás:
Megjelenítés
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nem elérhető
Név:
license.txt
Méret:
1.94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés
Gyűjtemények
Theses (Faculty of Pharmacy)